Welcome to LookChem.com Sign In|Join Free

CAS

  • or

2213-08-3

Post Buying Request

2213-08-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2213-08-3 Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 71, p. 2124, 1949 DOI: 10.1021/ja01174a061

Check Digit Verification of cas no

The CAS Registry Mumber 2213-08-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,1 and 3 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 2213-08:
(6*2)+(5*2)+(4*1)+(3*3)+(2*0)+(1*8)=43
43 % 10 = 3
So 2213-08-3 is a valid CAS Registry Number.
InChI:InChI=1/C6H13NO2/c1-3-9-6(8)4-5-7-2/h7H,3-5H2,1-2H3

2213-08-3Relevant articles and documents

Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core

Dyck, Brian,Grigoriadis, Dimitri E.,Gross, Raymond S.,Guo, Zhiqiang,Haddach, Mustapha,Marinkovic, Dragan,McCarthy, James R.,Moorjani, Manisha,Regan, Collin F.,Saunders, John,Schwaebe, Michael K.,Szabo, Tomas,Williams, John P.,Zhang, Xiaohu,Bozigian, Haig,Chen, Ta Rung

, p. 4100 - 4110 (2005)

Two new classes of tricyclic-based corticotropin-releasing factor (CRF 1) receptor-1 antagonists were designed by constraining known 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine ligands. Pyrrole- and pyrazole-based molecules 19g and

SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY

-

Page/Page column 87, (2016/03/29)

This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.

BISPHOSPHONATE COMPOUNDS FOR CHELATING RADIONUCLIDES

-

Page/Page column 42; 43, (2010/11/03)

Bisphosphonate compounds for chelating radionuclides are described which have separate bisphosphonate and metal chelating groups joined by a linker, so that the bisphosphonate groups are available to complex to hydroxyapatite in bone, while the metal chelating group binds to the radionuclide. This avoids problems in the prior art, where the bisphosphonate groups are used for both binding functions which compromises the bone-seeking activity of the bisphosphonate groups when they are used to chelate the radionuclide.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 2213-08-3